Figure 4.

Diagnostic performance of piR-13643 and piR-21238 in the training phase of the study. (A) The expression of piR-13643 is significantly upregulated in tumor tissue of papillary thyroid carcinoma patients compared to normal tissue (P < 0.001). (B) ROC analyses based on the expression of piR-13643 (AUC = 0.813). (C) The levels of piR-13643 increase significantly with advanced clinical stage (P = 0.0258). (D) The expression of piR-21238 is significantly upregulated in tumor tissue of papillary thyroid carcinoma patients compared to normal tissue(P < 0.001). (E) ROC analyses based on the expression of piR-21238 (AUC = 0.820). (F) The levels of piR-21238 decrease significantly with advanced clinical stage (P =0.0112). *P < 0.05; **P < 0.01; ***P < 0.001